Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.

Julie DubourgPascale FouquerayCarole ThangJean-Marie GrouinKohjiro Ueki

Published in: Diabetes care (2021)

Imeglimin significantly improved HbA1c in Japanese patients with type 2 diabetes compared with placebo and had a similar safety profile to placebo. Imeglimin represents a potential new treatment option for this population.

Keyphrases

double blind
placebo controlled
phase iii
clinical trial
phase ii
open label
combination therapy
phase ii study
study protocol
randomized controlled trial
squamous cell carcinoma
rectal cancer
replacement therapy